ABRACL as a potential prognostic biomarker and correlates with immune infiltration in low-grade gliomas

Background: Low-grade gliomas (LGGs) as one of the most common brain tumors and highly invade into adjacent normal brain tissue, which can result in low rate of radical excision and poor prognosis. Immunotherapy as a potential treatment method has garnered increasing attention in recent years. We systematically screened the prognostic genes based on 56,530 genes in CGGA database. Finally, ABRACL was selected as the target gene. ABRACL has not been investigated in gliomas. In our study, we aimed to explore the prognostic value of ABRACL. Methods: To analyse the prognostic value of ABRACL, gene expression profiles and clinical information of LGGs patients were collated from the TCGA and CGGA databases. Functional enrichment analysis was performed by using Gene Ontology (GO) and the Kyoto Encyclopedia of Genes and Genomes (KEGG). CIBERSORT algorithm was used to calculate the associations between ABRACL and immune cells infiltration. Then, we investigated the associations between ABRACL and immunomodulators. Four immunomodulators (TNFRSF14, TNFSF13, ULBP1, PDCD1LG2) were selected to establish the prognostic model which could be used to predict outcomes of LGGs patients.Conclusion: LGGs patients with high expression of ABRACL showed worse prognosis. ABRACL was an indepen-dent prognostic factor of LGGs. ABRACL played an important role in tumor immune microenvironment and promoted tumorigenesis and proliferation of LGGs by regulating the aggregation of macrophages M2. Functional enrichment analysis suggested that ABRACL was associated with various immune functions. Taken together, the results of this study showed that ABRACL was a potential novel biomarker of LGGs.